Myriad Genetics (MYGN) Current Deferred Revenue (2011 - 2022)

Myriad Genetics (MYGN) has reported Current Deferred Revenue for 12 consecutive years, with $200000.0 the latest figure, recorded in Q3 2022.

• In Q3 2022, Current Deferred Revenue fell 98.26% year-over-year to $200000.0; the TTM figure through Sep 2022 stood at $200000.0 (down 98.26% YoY), while the FY2021 annual figure was $5.2 million, down 84.1% from the prior year.
• Current Deferred Revenue slipped to $200000.0 in Q3 2022 per MYGN's latest filing, from $300000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $32.8 million in Q2 2020 and bottomed at $200000.0 in Q3 2022.
• Historically, Current Deferred Revenue has averaged $10.2 million across 5 years, with a median of $2.6 million in 2018.
• Annual changes were most pronounced in 2020 — Current Deferred Revenue soared 1438.1% — and 2022, when it slumped 98.67%.
• Myriad Genetics' Current Deferred Revenue stood at $2.4 million in 2018, then jumped by 50.0% to $3.6 million in 2019, then jumped by 808.33% to $32.7 million in 2020, then tumbled by 84.1% to $5.2 million in 2021, then sank by 96.15% to $200000.0 in 2022.
• Business Quant data shows MYGN's Current Deferred Revenue at $200000.0 in Q3 2022, $300000.0 in Q2 2022, and $700000.0 in Q1 2022.